KBC Group’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$126K Hold
3,310
– – ﹤0.01% 1259
2026
Q2
$156K Buy
3,310
+1,138
+52% +$28.1K ﹤0.01% 1150
2026
Q1
$41K Buy
+2,172
New +$36.9K ﹤0.01% 1722

Other funds holding DFTX

KBC Group's DFTX Position: Q3 2026 in Review

KBC Group held its Definium Therapeutics (DFTX) position steady in Q3 2026 at 3,310 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #1259.

KBC Group first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $156K in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • KBC Group held 3,310 shares of Definium Therapeutics worth $126K as of Q3 2026.
  • KBC Group left its Definium Therapeutics share count unchanged in Q3 2026.
  • Definium Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1259 holding.
  • KBC Group first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Definium Therapeutics position peaked at $156K in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.